Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fludrocortisone→

Fludrocortisone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
127-31-1
Molecular formula
C21H29FO5
Molecular weight
380.4 g/mol
Drug class
Synthetic mineralocorticoidglucocorticoid receptor agonist with strong mineralocorticoid activity
Mechanism of action
Activates mineralocorticoid receptors in the distal nephron, increasing sodium reabsorption and potassium/hydrogen ion excretion, thereby expanding extracellular fluid volume and supporting blood pressure. It also has glucocorticoid activity.
Indications / reported uses
  • Replacement therapy for mineralocorticoid deficiency in primary adrenal insufficiency (Addison disease) and selected forms of congenital adrenal hyperplasia
  • Selected off-label use for orthostatic hypotension; this is not a universal product-authorised indication

Sources: US DailyMed — Fludrocortisone acetate · NHS — Fludrocortisone · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fludrocortisone Environmental Risk Assessment (ERA) (the Fludrocortisone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.